BOSTON, February 8, 2022: Morgan Lewis represented Takeda Pharmaceutical Company Limited in its transaction with clinical-stage rare disease therapeutics company Oak Hill Bio.
Oak Hill Bio plans to advance a pipeline of clinical and preclinical investigational therapeutics acquired and licensed from Takeda. Takeda will receive an upfront payment and ownership stake in Oak Hill, as well as potential milestones and royalty payments, as consideration for the acquired and licensed programs.
The Morgan Lewis team advising Takeda with respect to the transaction was led by partners Suzanne Filippi, Russell Franklin, and David Glazer, with support from associates Esther Phu and Benjamin Stein.